VANCOUVER, British Columbia--(BUSINESS WIRE)--Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, today announced a project with Merck Research ...
Merck & Co. has doubled down on its partnership with Variational AI, striking a deal worth up to $349 million to collaborate on small molecule candidates against two targets. Variational disclosed a ...
The research team included, back row, from left, Shih-I (Harry) Tan, Nilmani Singh, Aashutosh Boob, and front row, from left, Teresa Martin, Li-Qing Chen, and Huimin Zhao. The mitochondrion, often ...
Merck & Co. is taking a look at a generative AI platform. As an early user of Variational AI’s technology, the Big Pharma will assess the ability of the platform to generate novel small molecules that ...
Disentangled variational autoencoder (D-VAE) separates materials properties from the latent space by conditioning to make inverse materials design more efficient and transparent. It combines labeled ...
VANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) a biopharmaceutical company committed to advancing new cancer therapies based on novel ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, today ...
Artificial intelligence (AI) is transforming our world, but within this broad domain, two distinct technologies often confuse people: machine learning (ML) and generative AI. While both are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback